# Dimethyl Sulfoxide Enhances HLA Peptide Identification

**Authors:** Terry C. C. Lim Kam Sian, Yue Ding, Scott A. Blundell, Ralf B. Schittenhelm, Pouya Faridi

PMC · DOI: 10.3390/proteomes14010013 · Proteomes · 2026-03-13

## TL;DR

Adding dimethyl sulfoxide (DMSO) to mass spectrometry workflows improves detection of HLA-bound peptides, enhancing sensitivity and reliability in immunopeptidomics.

## Contribution

Demonstrates that 5% DMSO in mobile-phase buffers systematically improves peptide identification and fragmentation in immunopeptidomics.

## Key findings

- DMSO increased peptide identifications by ~1.33-fold for HLA class I, ~1.55-fold for HLA class II, and ~1.24-fold for elastase digests.
- DMSO improved ionisation efficiency, charge states, and MS2 spectral quality with ~2-fold higher b- and y-ion intensities.
- DMSO did not introduce sequence bias, preserving motif integrity and binding characteristics of identified peptides.

## Abstract

Background: Mass spectrometry (MS)-based immunopeptidomics has emerged as the gold standard for profiling HLA-bound peptides, yet detection remains challenging due to their non-tryptic nature, variable lengths, and lack of basic residues, which limit ionisation and fragmentation efficiency. Methods: To address these limitations, we investigated the impact of incorporating 5% dimethyl sulfoxide (DMSO) into LC-MS/MS mobile-phase buffers on immunopeptidomic workflows. Using B-lymphoblastoid cell lines expressing HLA class I and II alleles and elastase-digested HeLa lysates as a surrogate for non-tryptic peptides, we assessed peptide identification, ionisation efficiency, charge state distribution, and fragmentation quality. Results: DMSO significantly increased peptide identifications across all sample types, with gains of ~1.33 folds for HLA class I, ~1.55 folds for HLA class II, and ~1.24 folds for elastase digests. Improvements were systematic and reproducible, driven by enhanced electrospray ionisation, higher charge states, and superior MS2 spectral quality, evidenced by ~2-fold increase in b- and y-ion intensities. Importantly, DMSO did not introduce major sequence bias, preserving motif integrity and predicted binding characteristics. Conclusions: Overall, these findings establish DMSO as a robust additive for improving sensitivity and reliability in immunopeptidomics, particularly for low-input or clinically derived samples.

## Linked entities

- **Chemicals:** dimethyl sulfoxide (PubChem CID 679), DMSO (PubChem CID 679)

## Full-text entities

- **Genes:** EGF (epidermal growth factor) [NCBI Gene 403657] {aka CEGF}, HLA-E (major histocompatibility complex, class I, E) [NCBI Gene 3133] {aka HLA-6.2, QA1}, HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}, HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}, HLA-S (major histocompatibility complex, class I, S (pseudogene)) [NCBI Gene 267015] {aka HLA-17}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, DLA-DRB1 (MHC class II DLA DRB1 beta chain) [NCBI Gene 474860] {aka DLA-DRBB1, DQB, DRB, DRB1, DRBB1, HLA-DRB1}
- **Diseases:** tumour (MESH:D009369), injury to (MESH:D014947)
- **Chemicals:** ACN (MESH:C032159), FA (MESH:D005492), lysine (MESH:D008239), peptides (MESH:D010455), DMSO (MESH:D004121), penicillin (MESH:D010406), cysteine (MESH:D003545), HCl (MESH:D006851), 2-chloroacetamide (MESH:C013874), CO2 (MESH:D002245), NaCl (MESH:D012965), nitrogen (MESH:D009584), formic acid (MESH:C030544), streptomycin (MESH:D013307), TFA (MESH:D014269), SDC (MESH:D003840), Cocktail (-), methionine (MESH:D008715), vitamin A (MESH:D014801), CHAPS (MESH:C028213), GlutaMAX (MESH:C054122), F-12 (MESH:C007782), HEPES (MESH:D006531), TCEP (MESH:C080938)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G) at position 8, C18, tyrosine (Y) at position 9, phenylalanine (F) at position 3, arginine (R) at position 5, glutamic acid (E) at position 3, S18V
- **Cell lines:** B-LCL — Homo sapiens (Human), Congenital disorder of glycosylation type Ia, Transformed cell line (CVCL_C0VF), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13030240/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13030240/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC13030240/full.md

---
Source: https://tomesphere.com/paper/PMC13030240